8-KMaterial AgreementsFinancial EventsOther Events+1

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Aug 12, 2020)

Filed August 12, 2020For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 11, 2020, reporting the issuance and sale of $2 billion in aggregate principal amount of senior unsecured notes. This issuance includes $1.25 billion of 1.750% Senior Notes due 2030 and $750 million of 2.800% Senior Notes due 2050. The net proceeds of approximately $1,977 million were primarily used to fully repay the $1.5 billion Sanofi Repurchase Bridge Facility, along with associated interest and fees. This debt issuance represents a significant financial maneuver for Regeneron, enabling it to refinance existing debt and potentially free up capital. The new notes are senior unsecured obligations, ranking equally with other senior unsecured debt but subordinate to secured debt and structurally subordinate to subsidiary obligations. The terms include redemption options and a change-of-control provision requiring a repurchase offer under specific circumstances.

Key Highlights

  • 1Regeneron issued $1.25 billion of 1.750% Senior Notes due 2030 and $750 million of 2.800% Senior Notes due 2050, totaling $2 billion in aggregate principal amount.
  • 2Net proceeds from the note offering were approximately $1,977 million.
  • 3The proceeds were used to fully repay the $1.5 billion Sanofi Repurchase Bridge Facility, plus accrued interest and fees.
  • 4The new notes are senior unsecured obligations of the company.
  • 5The 2030 Notes mature on September 15, 2030, and the 2050 Notes mature on September 15, 2050.
  • 6Interest on both series of notes is payable semi-annually.
  • 7The notes contain redemption provisions and a change-of-control repurchase option.

Frequently Asked Questions

The primary purpose of this debt issuance was to raise approximately $1.977 billion in net proceeds, which were then used to fully repay Regeneron's $1.5 billion Sanofi Repurchase Bridge Facility, along with related interest and fees. This allows the company to refinance existing debt.

Regeneron issued two series of senior unsecured notes: $1.25 billion of 1.750% Senior Notes due 2030 and $750 million of 2.800% Senior Notes due 2050. Interest is paid semi-annually, and the notes have specified maturity dates and can be redeemed under certain conditions.

The new notes are senior unsecured obligations and rank equally with Regeneron's other existing and future senior unsecured debt. They are effectively subordinated to all of the company's existing and future secured indebtedness and structurally subordinated to all existing and future obligations of Regeneron's subsidiaries.

Yes, the notes contain a change-of-control provision. Under certain circumstances, this provision may require Regeneron to offer to repurchase the notes at 101% of the principal amount plus accrued interest, providing some protection to noteholders in the event of a significant change in control of the company.